THERAVET SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.598 EUR | +0.34% |
|
-6.27% | -58.76% |
| May. 21 | TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study | CI |
| May. 07 | FOMO is Back |  |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 18.38 | 8.06 |
| Enterprise Value (EV) 1 | 13.75 | 5.922 |
| P/E ratio | - | -3.48 x |
| Yield | - | - |
| Capitalization / Revenue | 9.46 x | 5.03 x |
| EV / Revenue | 7.08 x | 3.7 x |
| EV / EBITDA | -8.51 x | -2.16 x |
| EV / FCF | -3,295,919 x | -2,806,956 x |
| FCF Yield | -0% | -0% |
| Price to Book | - | 1.07 x |
| Nbr of stocks (in thousands) | 3,224 | 3,224 |
| Reference price 2 | 5.700 | 2.500 |
| Announcement Date | 6/28/22 | 4/25/23 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net sales 1 | 0.7806 | 0.9878 | 1.943 | 1.602 |
| EBITDA 1 | -0.0888 | -0.3933 | -1.615 | -2.748 |
| EBIT 1 | -0.0953 | -0.4012 | -1.729 | -2.777 |
| Operating Margin | -12.21% | -40.62% | -89% | -173.35% |
| Earnings before Tax (EBT) 1 | -0.0984 | -0.389 | -1.468 | -2.35 |
| Net income 1 | -0.0989 | -0.3885 | -1.341 | -2.316 |
| Net margin | -12.67% | -39.33% | -69.02% | -144.57% |
| EPS | - | - | - | -0.7180 |
| Free Cash Flow | - | -0.2201 | -4.171 | -2.11 |
| FCF margin | - | -22.28% | -214.71% | -131.72% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 6/21/21 | 6/21/21 | 6/28/22 | 4/25/23 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net Debt 1 | 0.27 | - | - | - |
| Net Cash position 1 | - | 1.47 | 4.63 | 2.14 |
| Leverage (Debt/EBITDA) | -3.015 x | - | - | - |
| Free Cash Flow | - | -0.22 | -4.17 | -2.11 |
| ROE (net income / shareholders' equity) | - | -15.7% | -20.6% | -27% |
| ROA (Net income/ Total Assets) | - | -6.97% | -13% | -16.6% |
| Assets 1 | - | 5.576 | 10.28 | 13.98 |
| Book Value Per Share | - | - | - | 2.330 |
| Cash Flow per Share | - | - | - | 0.9900 |
| Capex | - | 0.02 | 0.01 | 0.01 |
| Capex / Sales | - | 1.82% | 0.51% | 0.36% |
| Announcement Date | 6/21/21 | 6/21/21 | 6/28/22 | 4/25/23 |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -58.76% | 2.09M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- ALVET Stock
- Financials TheraVet SA
